Latest Health News
Phase 1 Nipah vaccine shows safety and strong immune response
A HeV sG V candidate vaccine against Nipah virus was safe and immunogenic in a phase 1 trial, prompting calls for larger phase 2 studies to assess protection in high‑risk regions, according to reporting of The Lancet study and summary coverage in today's medical bulletins.
WHO updates HIV clinical management recommendations
WHO published updated recommendations aiming to optimize antiretroviral therapy and simplified clinical approaches for HIV care to support public‑health implementation worldwide.
Novel neonatal lung therapy reverses bronchopulmonary dysplasia in mice
Researchers reported in Cell Stem Cell that restoring full‑length NTRK2 using lipid nanoparticle mRNA promoted lung blood‑vessel growth and reversed BPD-like injury in mice, advancing isoform‑specific RNA therapy prospects for premature infants.
U.S. announces major new health pacts with four African countries
The U.S. committed roughly $1.4–$2.3 billion in new health agreements with Madagascar, Sierra Leone, Botswana and Ethiopia to strengthen health systems and programs across the region, according to reporting on new pacts.
ProMED highlights multiple ongoing infectious outbreaks worldwide
ProMED's alerts list recent events including avian influenza, African swine fever, cholera, diphtheria and Lassa fever outbreaks across Asia, Africa and the Americas, underscoring continuing global infectious‑disease risks.
Breakthroughs in gynecologic oncology reshape treatment choices
2025 saw significant advances—new maintenance regimens and antibody‑drug conjugates improved outcomes in endometrial and platinum‑resistant ovarian cancers, expanding options for hard‑to‑treat gynecologic malignancies.
Genomics and AI deliver potent new tools for gene editing
CRISPR‑GPT and other AI‑assisted genomics tools accelerated gene editing and experimental design in 2025, while advances in base and prime editing received high recognition in the field.
Research points to viral contributors to long COVID symptoms
Scientists reported mounting evidence that hidden or reactivated viral infections—such as Epstein‑Barr virus—may contribute to persistent long COVID symptoms, suggesting new diagnostic and therapeutic directions.
New cancer nanotherapy kills tumor cells while sparing healthy tissue
Researchers developed tiny metal‑based nanoparticles that selectively push cancer cells to death while mostly sparing healthy cells, reported in ScienceDaily as a promising preclinical advance in oncology.
Clearmind reports progress on non‑hallucinogenic neuroplastic therapy for AUD
Clearmind Medicine announced Phase I/IIa trial progress for CMND‑100, a non‑hallucinogenic MEAI‑based oral candidate for alcohol use disorder, reporting favorable safety and DSMB endorsement of continued study.
FDA approvals and new drugs change allergy and urticaria care
2025 approvals—such as the BTK inhibitor remibrutinib for chronic spontaneous urticaria—and promising biologics like dupilumab alternatives advanced targeted care for allergic diseases, summarized in specialty recaps.
ScienceDaily highlights top health research including immune and metabolic findings
ScienceDaily's roundup covered diverse 2025 findings: immune‑cell impacts from stress, mitochondrial uncouplers for obesity, and other translational studies shaping near‑term clinical research priorities.